AIDS across Europe, 1994-98: the EuroSIDA study (Q33924705)

30 July 2017

AIDS across Europe, 1994-98: the EuroSIDA study (English)

1 reference

30 July 2017

0 references

A Chiesi

7

0 references

Christine Katlama

2

object named as

C Katlama

1 reference

30 July 2017

10

J D Lundgren

1 reference

30 July 2017

9

O Kirk

1 reference

30 July 2017

1

A Mocroft

1 reference

30 July 2017

A M Johnson

3

1 reference

30 July 2017

C Pradier

4

1 reference

30 July 2017

F Antunes

5

1 reference

30 July 2017

F Mulcahy

6

1 reference

30 July 2017

A N Phillips

8

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

30 July 2017

1 reference

30 July 2017

356

1 reference

30 July 2017

291-296

1 reference

30 July 2017

9226

1 reference

Staging system for clinical AIDS patients

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Incidence Of Clinical Aids Conditions In A Cohort Of Homosexual Men With CD4+ Cell Counts <100/mm3

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Natural history of opportunistic disease in an HIV-infected urban clinical cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Serial CD4 lymphocyte counts and development of AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Opportunistic infections occurring during highly active antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Has the Spectrum of AIDS-Defining Illnesses Been Changing Since the Introduction of New Treatments and Combination of Treatments?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Changes in use of antiretroviral therapy in regions of Europe over time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Risk of new AIDS diseases in people on triple therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Epstein-Barr virus in AIDS-related primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902504-6

7 January 2021

10.1016/S0140-6736(00)02504-6

Identifiers

DOI

1 reference

30 July 2017

1 reference